"Xmas" is not a modern attempt to remove Christ from Christmas but a sacred abbreviation rooted in early Christian tradition, using the Greek letter chi to represent "Christos." ...

It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt. An FDA advisory committee ...

The project aims to produce a record of the Celtic languages spoken in Britain and Ireland, though the majority of these ...

Naver is accelerating the advancement of its 'knowledge infrastructure,' including dictionaries and encyclopedias. Leveraging ...

Researchers started to create the world’s first dictionary of Celtic languages, offering extraordinary insights into the ...

“We don't really know at what point Celtic emerged. The earliest extant texts in a Celtic language date from the early sixth century BCE, from northern Italy, a language that modern scholars call ...

The first complete dictionary of the ancient Celtic languages of Britain and Ireland is being made. Ancient Celtic languages ...

Abstract: Sentiment analysis, a subfield of Natural Language Processing (NLP), focuses on the study of emotions expressed in text data. While extensively used in major languages such as English, its ...

Lexicon Pharmaceuticals is positioned for a potential turnaround with three key drug programs and recent partnerships, despite a challenging history. LXRX's sotagliflozin faces uncertain FDA approval ...

Lexicon Pharmaceuticals is yet again defending a mixed set of data on its non-opioid pain prospect. The biotech focused on low-dose results from its latest phase 2 trial, rather than the overall ...

Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) shares are trading lower by 42% to 40 cents Monday morning. The company earlier announced topline results from its PROGRESS Phase 2b study evaluating ...